Objectives This study sought to compare everolimus-eluting stents (EES) versus Resolute zotarolimuseluting stents (ZES) in terms of patient-or stent-related clinical outcomes in an "all-comer" group of patients with diabetes mellitus (DM) who underwent percutaneous coronary intervention.
Implantation of drug-eluting stents (DES) has demonstrated superiority in reducing the need for repeat revascularization compared with bare-metal stents in substudies of randomized controlled trials (RCT), a multicenter observational registry, and meta-analysis in patients with diabetes mellitus (DM) (1) (2) (3) (4) . Nonetheless, DM is still among the most important risk factors for adverse clinical events, even in the DES era (5, 6) . Second-generation DES have almost completely replaced first-generation DES, in the treatment of coronary artery disease. The representative second-generation DES, everolimus-eluting stents (EES) have shown noninferior or comparable clinical outcomes with first-generation DES in patients with DM (7, 8) .
Another second-generation DES, the Resolute zotarolimus-eluting stent (ZES), recently received U.S. Food and Drug Administration labeling for use in patients with DM (9 (12) . To the best of our knowledge, there are limited data regarding direct comparison of EES with ZES in patients with DM. Therefore, we compared EES versus ZES in terms of patient-and stentrelated clinical outcomes in all-comers with DM undergoing percutaneous coronary intervention (PCI) with secondgeneration DES.
Methods
An extended description of study methods are presented in the Online Appendix. Study design and patient population. This study evaluated 1-year clinical outcomes of EES (Xience V, Abbott Vascular, Abbott Park, Illinois) and zotarolimus-eluting stents (ZES) (Resolute, Medtronic Cardiovascular, Minneapolis, Minnesota) in the patients with DM from the EXCELLENT and RESOLUTE-Korea registries, which enrolled all-comers treated with !1 EES or ZES (3, 056 patients in 29 participating centers and 1,998 patients in 25 participating centers, respectively) without exclusions (12) . Among the 5,054 patients, 36.7% (n ¼ 1,855) had type 2 DM and were treated with EES (1,149 of 3,056 patients, 37.9%) or ZES (706 of 1,998 patients, 35.3%). The flow of patients in the study is presented in Figure 1 . Follow-up. After index PCI, follow-ups were performed at 1, 3, 9, and 12 months; angiography was optional at 9 months. All relevant medical records were reviewed for any clinical event and adjudicated by an external clinical event committee. Using the Korean health system's unique identification numbers, the vital status of all patients was cross-checked. The study protocol was approved by the ethics committee at each participating center and was conducted according to the principals of the Declaration of Helsinki. All patients provided written informed consent. Definitions and outcome analysis. DM (type 1 or type 2) was defined as either a previous diagnosis of DM treated with pharmacologic or nonpharmacologic measure, or a new DM was defined according to the American Diabetes 
Association as history of either presence of classic symptoms of DM with unequivocal elevation of plasma glucose (2 h post-prandial or random of >200 mg/dl) or fasting plasma glucose elevation on >2 occasions of !126 mg/dl during hospitalization. Patients were considered insulin-treated if they were taking insulin. Patients were considered noninsulin-treated if they were taking only oral hypoglycemic agents or were on a therapeutic lifestyle modification only or both oral agents and therapeutic life-style modification. The primary stent-related clinical outcome was target lesion failure (TLF), defined as cardiac death, target vessel myocardial infarction (MI), or clinically indicated target lesion revascularization (TLR) by percutaneous or surgical methods at 12 months. All clinical outcomes were defined according to the Academic Research Consortium (13, 14) . The key secondary outcomes were patient-oriented composite events, which included all-cause mortality, any MI, and any revascularization. Other secondary outcomes included individual components of the primary and key secondary clinical outcomes; target or non-target vessel MI; clinically driven or angiographically driven repeat revascularization including TLR or target vessel revascularization (13) ; and stent thrombosis (ST) defined according to the Academic Research Consortium as definite, probable, or possible (13, 14) . The indication of PCI was considered "offlabel" if any of the following features were present: serum creatinine concentration !140 mmol/l (1.6 mg/dl); left ventricular ejection fraction <30%; an acute MI within the previous 72 h; >1 lesion per vessel; !2 vessels treated with a stent; a lesion length !28 mm; or a bifurcated lesion, bypass graft, in-stent restenosis, unprotected left main coronary artery, presence of thrombus, or total occlusion (15, 16) . Chronic renal failure was defined as an estimated glomerular filtration rate <60 ml/min calculated by means of the Cockcroft-Gault formula. Statistical analysis. The analysis was performed in 2 parts. First, analysis and comparison of primary and secondary clinical outcomes were conducted in the crude population. Second, a propensity score matched population was selected to adjust for uneven distribution of baseline characteristics. Comparison of treatment effect between 2 stent groups was stratified by DM versus non-DM. Categorical variables were presented as numbers and relative frequencies (percentages) and were compared using the chi-square test or the Fisher exact test for independent groups and a 2-tail p value. Normally distributed continuous variables were expressed as means AE SD and were analyzed using the independent sample t test. Kaplan-Meier analysis was used to calculate cumulative incidence of primary and secondary clinical outcomes, and log-rank test or Breslow test was used to compare between-group differences, as appropriate. Because differences in baseline clinical and angiographic characteristics could affect the primary and secondary clinical outcomes, a 1:1 matched analysis without replacement was performed using propensity scores. The propensity scores were estimated with multiple logistic regression analysis that included all covariates listed in Tables 1 and 2 , except outcome variables. Logistic regression model was separately conducted to generate a propensity score, which was the probability that a patient received a ZES or which was the probability that a patient had DM. The discrimination and calibration abilities of the propensity score model were assessed by C-statistics (0.652 for the first model according to the stent types and 0.705 for the second model according to the presence or not of DM) and the Hosmer-Lemeshow statistics (chi-square: 8.375, p ¼ 0.398 and chi-square: 7.107, p ¼ 0.525, respectively). The matching processes were also performed separately to compare the clinical outcomes between EES and ZES, or between patients with or without DM. For matching, nearest neighbor matching with a caliper width of 0.6 SD was used because this value has been shown to eliminate over 90% of the bias in the observed confounders (17) . Success of the propensity score matching was assessed by calculating the percentage of standardized differences of the baseline characteristics. A <10% difference supports the assumption of a balance between matched groups (18) . A Cox proportional hazard regression model was used to identify independent predictors of primary clinical outcome TLF. The covariates used in multivariate analysis were selected if they were Park et al.
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significantly different between the 2 groups (p < 0.1) or if they had predictive values. All probability values were 2-sided and p values < 0.05 were considered statistically significant. The statistical package SPSS (version 18.0, SPSS Inc., Chicago, Illinois) and R programming language (version 2.15.2, R Foundation for Statistical Computing, Vienna, Austria) were used for statistical analyses.
Results
Baseline patient and angiographic characteristics of diabetes population. Among the overall population of both registries (n ¼ 5,054), the final analysis population was 1,855 patients with DM with 2,688 lesions (EES: 1,149 patients with 1,660 lesions, ZES: 706 patients with 1,028 lesions), and 3,174 nondiabetic patients with 4,365 lesions (EES: 1,882 patients with 2,557 lesions, ZES: 1,292 patients with 1,808 lesions), after exclusion of the patients with unknown status of DM. In the overall population of 5,054 patients, 55 (1.1%) in the EES group and 32 (0.6%) patients in the ZES group, respectively, were lost to follow-up before the 12-month follow-up visit; however, all were confirmed alive.
Baseline clinical and angiographic characteristics are presented in Tables 1 and 2 , respectively. Among the 1,855 patients, 209 patients (11.3%) were newly diagnosed with DM according to the criteria of the American Diabetes Association at the time of index procedure. Although the proportion of dyslipidemia was higher in the ZES group, the mean low-density cholesterol level was similar between the 2 groups. In addition, the ZES group 
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had a slightly higher baseline risk, including higher frequency of ST-segment elevation MI patients, bifurcation lesions, and longer stent length. PCI was also more often off-label in the ZES group. However, type B2 or C lesions were more common in the EES group (Tables 1 and 2) . Overall, acute coronary syndrome accounted for 60.3%, and PCI was off-label in 77.7% of the cases. Patients with multivessel disease accounted for 62.8%, and the mean stent length was 41.1 AE 26.7 mm per patient, all of which were significantly higher in the patients with diabetes than in nondiabetic patients in both stent groups. The large proportion of high-risk patients and lesions suggests that our study patients were an enriched PCI population, reflecting real-world practice in Korea without any exclusion or restriction. In addition, 37.1% of the cases were performed under intravascular ultrasound guidance.
Despite the large proportion of high-risk patients and lesions, the device, lesion, and procedure success rates were excellent for both stents and did not show between-group differences ( Table 2) . Park et al.
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M A Y 2 0 1 4 : 4 7 1 -8 1 due to ST (Table 3) . In nondiabetic patients, the incidence of TLF was also comparable between the 2 stent groups (Fig. 2) . However, both stent groups did not show any differences in the cumulative incidence of TLF or patient-oriented composite events, both in the diabetic and nondiabetic patients (Fig. 2) . The survival curves of individual components of TLF or patient-oriented composite events are presented in Online Figure 1 . The incidence of Academic Research Consortiumdefined definite or probable ST through 1 year was very low, regardless of diabetes: the rates of ST were 0.5% (10 of 1,855 patients) for the diabetic patients and 0.5% (15 of 3,174 patients) in the nondiabetic patients. In diabetic patients, there was a numerically higher rate of definite or probable ST in the EES group without statistical significance (0.8% vs. 0.1%, p ¼ 0.100) ( Table 4) . However, the incidence of ST did not show any clustering of events in nondiabetic patients (0.5% vs. 0.5%, p ¼ 0.956). All diabetic patients with ST were on dual antiplatelet therapy, except in 1 case in which both agents were discontinued due to spontaneous subdural hemorrhage 2 days after PCI. A detailed description of all ST cases in the patients with DM is presented in Online Table 1 .
Notably, the subgroup of insulin-treated patients (n ¼ 255) showed similar rates of TLF and patient-oriented composite events compared with the non-insulin-treated patients (TLF: 4.3% vs. 3.6%, p ¼ 0.589, patient-oriented composite events: 10.2% vs. 9.4%, p ¼ 0.730 for insulin-vs. non-insulin-treated patients, respectively). Conversely, patients with chronic renal failure showed significantly higher incidence of both TLF (9.3% vs. 3.3%, p < 0.01) and patient-oriented composite events (14.7% vs. 9.2%, p ¼ 0.038) (Fig. 3) . Propensity score matched group analysis. Propensity score matching, according to the type of stents, yielded 934 patients (467 pairs) with more balanced baseline characteristics (Online Table 2 ). All standardized differences of the 44 adjusted variables were <10% (Online Fig. 2) . At 1 year, TLF occurred in 3.9% and 3.4% (RR: 0.89, 95% CI: 0.46 to 1.72, p ¼ 0.862) and patient-oriented composite events in 9.4% and 8.6% (RR: 0.91, 95% CI: 0.60 to 1.37, p ¼ 0.732) in the EES and ZES groups, respectively. The individual components of both TLF and patient-oriented composite events, and the incidence of definite and probable ST were also similar (Online Table 3 ). In the survival analysis, cumulative incidences of TLF or patient-oriented composite events were comparable between the EES and ZES groups, regardless of the presence of diabetes (Fig. 2) .
To minimize the risk of bias in comparing diabetic and nondiabetic patients, both groups were matched according to the presence of DM. As a result, 2,774 patients were matched (1,387 patients with or without DM, respectively) with more balanced baseline characteristics (Online Table 4 ). As expected, except for significantly higher hemoglobin A 1C level in the diabetes group, standardized differences of baseline characteristics were <10% (Online Fig. 2 ). Both TLF (3.6% in diabetic patients vs. 1.9% in nondiabetic patients, respectively, RR: 1.85, 95% CI: 1.17 to 2.94, p ¼ 0.008) and patient-oriented composite events (9.0% vs. 6.2%, RR: 1.45, 95% CI: 1.12 to 1.89, p ¼ 0.005) Values are n (%). *Target lesion failure defined as a composite of cardiac death, MI (not clearly attributed to a nontarget vessel), or clinically indicated target lesion revascularization by percutaneous or surgical methods at 1 year. yPatient-oriented composite events included all-cause mortality, any MI (includes nontarget vessel territory), and any revascularization (includes all target and nontarget vessel, regardless of percutaneous or surgical methods).
CI ¼ confidence interval; MI ¼ myocardial infarction; RR ¼ relative risk; ST ¼ stent thrombosis.
were significantly higher in the patients with diabetes than in the nondiabetic patients (Online Table 5 ). In addition, the patients with DM showed significantly higher incidence of target vessel MI and target vessel revascularization (Online Table 5 ). Table 4 ). The overall Harrell C-index of the model was 0.780 (95% CI: 0.699 to 0.861).
Discussion
This is the first comprehensive registry analysis evaluating the safety and efficacy of EES (Xience V EES) versus ZES (Resolute ZES) in the patients with DM. Our results demonstrated that EES and ZES showed comparable results regarding stent-and patient-related composite outcomes at 1 year in the patients with DM, both in the crude and propensity score matched populations. Although the incidences of TLF or patient-oriented composite events were significantly higher in the patients with DM than in the nondiabetic patients, the overall incidence was low, suggesting excellent safety and efficacy of both types of second-generation DES in this high-risk subgroup of patients. In addition, the patient-related outcomes were about 3-fold higher than the stent-related outcomes (TLF) were, suggesting the importance of secondary prevention and integrated medical management of comorbidities along with DM, including diabetic nephropathy, hypertension, and peripheral arterial disease. Finally, the chronic renal failure was the strongest predictor of TLF within 1 year in the patients with DM.
The safety and efficacy of the second-generation DES in the patients with DM have been continuously evaluated. The EES was shown to be noninferior to sirolimus-eluting stent for in-segment late loss at 8 months in the ESSENCE-DIABETES (Randomized Comparison of Everolimus-Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery Disease in Patients With Diabetes Mellitus) trial (7) . Although underpowered for clinical outcomes, death, MI, and TLR were not significantly different between EES (Xience V) and sirolimus-eluting stents. Also post-hoc subgroup analysis from 4 pooled RCT, comparing EES versus paclitaxeleluting stent, showed no difference in clinical outcomes after 2 years of follow-up between EES and paclitaxel-eluting stents (8) . On the other hand, ZES (Resolute) have showed significantly lower incidence of target vessel failure at 1 year (7.8%) than the pre-defined DES performance goal of 14.5% in the patients with DM and achieved the first U.S. Food and Drug Administration approval for PCI in patients with diabetes (9) . Although both of the second-generation DES, compared with first generation DES, have shown improved clinical outcomes in the diabetic patients, the data regarding head-to-head comparison of these stents in the patients with DM have been limited. The representative direct comparisons of EES versus ZES (i.e., Resolute AllComers and TWENTE trials) did not focus on the diabetic subgroup. The proportion of the patients with DM was limited to 538 patients (23.4%) in the Resolute All-Comers trial and 301 patients (21.6%) in the TWENTE trial, which were relatively underpowered to compare clinical outcomes in the diabetic population. In addition, it is well known that patients with higher-risk profiles and higher early inhospital mortality tend to be excluded from participation in clinical trials, even with all-comers design (19) . We evaluated 1,855 diabetics with 2,688 lesions, and the majority of patients had !1 off-label indication (77.7%), and there was no restriction or exclusion criteria regarding disease severity or lesion complexity. In addition, over 98% of the patients were strictly followed, and the survival status of all patients was thoroughly investigated. In this regard, this analysis of prospective observational registries has the strength of including a broader patient population with quite a large sample size, which is more reflective of everyday practice, compared with former RCT. Interestingly, insulin-treated patients showed numerically higher but statistically insignificant rates of TLF and patient-oriented composite events. Previous trials using Conversely, recent pooled analysis of patient-level data from the RESOLUTE Global Clinical Program showed significantly higher incidence of target vessel failure (16.4% versus 10.4%, p ¼ 0.02) or TLF (13.5% versus 7.9%, p ¼ 0.01), mainly driven by higher incidence of cardiac death or target vessel MI (3.9% vs. 8.6%, p ¼ 0.01), in the insulin-treated patients after 2 years following ZES implantation (9) . Whether insulin-dependency significantly affects outcome of PCI with second-generation DES needs to be clarified in larger-scale data.
On multivariate analysis, several factors were found to significantly increase the risk of TLF including chronic renal failure, in-stent restenosis, left main vessel PCI, and small vessel diameter. Chronic renal failure and left main vessel PCI have been well-recognized risk factors for major adverse cardiac events (20) and angiographic restenosis (21) after stent implantation in both the bare-metal stent era and the first-generation DES era. Small vessel stenting may lead to increased risk of periprocedural myocardial necrosis and has been reported to be a risk factor for ST (22) . Because diabetic patients tend to have smaller vessel diameters, this could adversely affect the long-term clinical outcomes, as was corroborated in our results. Treatment of in-stent restenosis requires stent implantation in an area that has previously been stented. This can result in injury zone mismatch, a gap between the stents, fracture of the stent, polymer disruption, or a combination of these mechanisms (23) . Thus, treatment of in-stent restenosis lesions still remains a challenge even in the DES era. All things considered, however, the low rates of both stent-and patient-oriented outcomes in the present analysis reaffirms that the development of a new generation of DES has been in the right direction. Nonetheless, more investigation about long-term clinical outcomes after PCI with second-generation DES in insulin-treated diabetic patients is needed. Study limitations. First, this was a nonrandomized comparison of 2 different registries. Therefore, this study cannot be free from inherent limitations of observational registries such as allocation bias and uneven distribution of risk factors. Although we used propensity score matching to minimize the allocation bias and control for potential confounding variables, the possibilities of uncontrolled and unknown confounding factors need to be considered. Second, analysis of clinical outcome was limited to 1 year after index PCI. Our study is not able to make any conclusions regarding long-term prognosis over 1 year in diabetic patients. Further follow-up is required, especially to address safety issues such as ST. Third, because data were from observational registries, the clinical events may not have been captured with scrutiny, and patient follow-up may not have been as strict as would be in a randomized trial. This may have been the reason for the low event rates, especially the rate of target lesion-related MI, which was much lower in our study than in the previous RCT and pooled analysis of EES and ZES (8) (9) (10) (11) . We believe that this may be due to the fact that systematic collection of cardiac enzymes after PCI is not the routine practice in Korea. Some centers even discharge their patients on the same day after PCI via the radial approach. Therefore, we believe the true rate of MI would have been much higher if the cardiac enzymes were followed systematically. Although we cross-checked the vital Table 6 . yHazard ratio of EES over ZES-R in crude population. In propensity score matched group, the hazard ratio of EES over ZES-R was 1.237 (95% CI: 0.595 to 2.571, p ¼ 0.570).
Abbreviations as in Tables 1 and 3 .
Park et al. status of 100% of the study patients with the Korean national database using a citizen registration number that is unique to each individual, we cannot exclude the possibility of under-reporting of clinical outcomes other than death such as MI, TLR, or most importantly, ST, in the patients who were lost to follow-up but are still alive. Lastly, although we thoroughly collected baseline and discharge medication data including dual antiplatelet agents, we did not include cilostazol as 1 of the parameters to collect, therefore, the clinical efficacy of triple antiplatelet agent in diabetic patients could not be evaluated.
Conclusions
After unrestricted use of second-generation DES in allcomers receiving PCI, both EES and ZES showed comparable clinical outcomes in the patients with DM up to
